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Abstract
Background: The function of preadipocytes in the progression of early stage breast cancer has not been fully
elucidated at the molecular level. To delineate the role of preadipocytes in breast cancer progression, we investigated
the cross-talk between human breast ductal carcinoma in situ (DCIS) cells and preadipocytes with both an
in vitro culture and xenograft tumor model.
Methods: GFP or RFP was transduced into human DCIS cell line MCF10DCIS.com cells or preadipocytes using
lentivirus. Cell sorter was used to separate pure, viable populations of GFP- or RFP-transduced cells. Cell viability and
proliferation was assessed by crystal violet assays and cell migration and invasion capability was assayed by
the transwell strategy. Gene and protein levels were measured by western blot, RT-PCR and immunostaining.
Adipokines and cytokines were quantified using ELISA. Human tumor xenografts in a nude mice model were used.
Ultrasound imaging of tumors was performed to evaluate the therapeutic potential of a IL-6 neutralizing antibody.
Results: In the co-culture system with the MCF10DCIS.com and preadipocytes, MCF10DCIS.com proliferation, migration
and invasion were enhanced by preadipocytes. Preadipocytes exhibited in an increased IL-6 secretion and cancer-
associated fibroblast markers expression, FSP1 and α-SMC in co-culture with MCF10DCIS.com or in MCF10DCIS.
com conditioned media, whereas the adipocyte differentiation capacity was suppressed by co-culture with
MCF10DCIS.com. A neutralizing antibody of IL-6 or IL-6R suppressed the promotion of MCF10DCIS.com proliferation
and migration by co-culture with preadipocytes. In the xenograft tumor model, the tumor growth of MCF10DCIS.com
was enhanced by the co-injection of preadipocytes, and the administration of IL-6 neutralizing antibodies resulted in
potent effects on tumor inhibition.
Conclusions: Our findings suggest that IL-6-mediated cross-talk between preadipocytes and breast DCIS cells
can promote the progression of early stage breast cancer. Therefore, blocking IL-6 signaling might be a potential
therapeutic strategy for breast DCIS characterized by pathological IL-6 overproduction.
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Background
Ductal carcinoma in situ (DCIS), known as intraductal car-
cinoma, is defined as the proliferation of neoplastic epithe-
lial cells within the breast milk duct. Because DCIS may
develop into invasive breast cancer within 5 to 10 years
after the initial diagnosis, it is generally recommended that
patients with DCIS receive treatment [1]. Based on molecu-
lar, epidemiological, and pathological studies [2], DCIS is
thought to be an early form of breast cancer, but very little
is known about the factors that promote survival in DCIS
neoplastic cells.
Identifying the tumor microenvironmental regulators of
DCIS progression is critical for determining a predictive
molecular signature and for treating patients with DCIS.
The most abundant stromal constituent in the breast is
adipose tissue. Adipose tissue is an endocrine organ that is
primarily composed of heterogeneous cells, including adi-
pocytes and preadipocytes [3]. Recent evidence highlights
the adipose tissue surrounding tumors as a key compo-
nent in breast cancer progression [4–6]. While there is
extensive literature on the association of adipose tissue
with the invasiveness and the dissemination of breast
cancer cells by leptin, hepatocyte growth factor (HGF),
collagen VI, interleukin-6 (IL-6) and C-C motif chemo-
kine 5 (CCL5) secreted from adipocytes as well preadipo-
cytes isolated from abdominal and breast adipose tissue
[7–13], little is known about the DCIS progression to
invasive breast cancer by cross-talk with preadipocytes. A
recent study documented that preadipocytes promote the
DCIS progression to breast cancer via exosomal signaling
[14], implying association of preadipocytes-secreted fac-
tors with the development of breast cancer in early stage.
The contribution of factors secreted from human prea-
dipocytes to breast cancer progression at early stage is
largely unknown. A better understanding of the cross-talk
between preadipocytes and human DCIS cells is essential
to clarify targets and strategies for preventing the
pro-tumorigenic effect of preadipocytes. Thus, this study
aimed to investigate the preadipocyte-derived factors that
drive cell migration and proliferation in cultured human
DCIS cells and tumor progression in xenograft models
and to evaluate if the inhibition of preadipocyte-derived
factors can prevent breast cancer development.
Methods
Cell culture
Human DCIS cell line MCF10DCIS.com (Asterand, De-
troit, MI) which designated as DCIS.com, was cultured
in DMEM/F12 supplemented with 5% heat-inactivated
horse serum (Invitrogen, Carlsbad, CA), 4 μg/ml insulin
(Gibco, Grand Island, NY), 100 ng/ml cholera toxin,
0.5 μg/ml hydrocortisone (Sigma, St. Louis, MO), and
20 ng/ml EGF (Life Technologies, Grand Island, NY).
Normal human preadipocytes (hPreAd) isolated from
subcutaneous fat from healthy (non-diabetic) donors
were purchased from Lonza (Walkersville, MD) and
were grown in BulletKit™ media. In this study, DCIS.-
com/RFP and hPreAd/GFP cells were generated using
lentiviruses carrying RFP and GFP, respectively. Briefly,
lentiviral vectors containing the RFP or GFP construct
were purchased from Addgene (Cambridge, MA) to es-
tablish RFP-transduced DCIS.com and GFP-transduced
preadipocytes. Lentiviral production and transduction
was conducted according to the manufacturer’s instruc-
tions (Invitrogen, Carlsbad, CA). At 7 days after lenti-
viral transduction RFP- or GFP-positive cells were
sorted using a FACSCalibur flow cytometer (BD Biosci-
ences, Franklin Lakes, NJ). Cells that stably expressed
RFP or GFP were generated for use in in vitro subse-
quent studies.
Proliferation assay
To investigate alterations in DCIS.com and hPreAd prolif-
eration in co-culture conditions, a proliferation assay was
performed using transwell chambers with 4-μm pore size
insert (Costar, Cambridge, MA). For a proliferation assay
of DCIS.com in co-culture, the DCIS.com (0.5 × 105 cells/
ml) was seeded in the bottom of 24-well transwell plates
and the hPreAd in the upper chamber. To test the hPreAd
proliferation, the hPreAd (0.5 × 105 cells/ml) were loaded
in the bottom of 24-well transwell plates and the DCIS.-
com in the upper chamber. To evaluate the alterations in
DCIS.com proliferation mediated by IL-6, DCIS.com were
cultured in medium containing recombinant human IL-6
(50 ng/ml) (R&D Systems, Minneapolis, MN) for 48 h,
and transwell co-cultures were performed with hPreAd in
the presence or absence of IL-6 neutralizing antibody
(NAb) (3 μg/ml) (R&D Systems, Minneapolis, MN) or
IL-6R NAb (3 μg/ml) (R&D Systems, Minneapolis, MN)
for 48 h. Cells in the lower chamber were stained with 1%
crystal violet in methanol/PBS. Crystal violet was then
dissolved with a 0.1% SDS solution, and the absorbance
was read at 570 nm.
Migration and invasion assay and confocal microscopy
imaging
DCIS.com migration in co-culture with hPreAd was
assessed in transwell chambers with an 8-μm pore size
insert (Costar, Cambridge, MA). DCIS.com (0.5 × 105
cells/ml) was seeded into the top chamber, and the lower
chamber contained hPreAd (0.5 × 105 cells/ml). To evalu-
ate the IL-6-mediated alterations in DCIS.com migration,
DCIS.com was cultured in medium containing IL-6
(50 ng/ml) for 48 h, and transwell co-cultures with
hPreAd in the presence or absence of IL-6 NAb (3 μg/ml)
or IL-6R NAb (3 μg/ml) for 48 h were performed. To
assess the invasion assay, DCIS.com was seeded in the
upper chamber containing 2% Matrigel (BD Biosciences,
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Billerica, MA). The migrated cells were stained with 1%
crystal violet in methanol/PBS. Crystal violet was then
dissolved with a 0.1% SDS solution, and the absorbance
was read at 570 nm.
For live imaging of DCIS.com invasion across
three-dimensional (3D) Matrigel which mimic the in vivo
cellular environment into hPreAd, hPreAd was seeded in
an 8-well chamber slide, 2% Matrigel (274-μm-thick) was
added, and DCIS.com was seeded onto the Matrigel. Con-
focal images were obtained using an LSM700 microscope
(Zeiss, MJena, Germany), and 3D reconstructions were
performed from confocal z-series stacks (20–25 μm) by
scanning at 1-μm intervals.
3D culture
A layer of growth factor-reduced Matrigel was made for
3D on-top Matrigel cultures [14]. In brief, 24-well
culture plates were coated with a thin layer of Matrigel
(120 μl) and incubated for 15–30 min at 37 °C to allow
the Matrigel to solidify. The mixture of DCIS.com (5–
6 × 106 cells/ml) and Matrigel was added onto the
pre-coated surface. After hPreAd were cultured for 72 h,
the culture supernatants of hPreAd were concentrated
and conditioned media of hPreAd were prepared. After
incubating for 30 min at 37 °C to allow the Matrigel to
gel, the appropriate volume of hPreAd conditioned
media containing IL-6 (50 ng/ml), IL-6 NAb (3 μg/ml)
or IL-6R NAb (3 μg/ml) was added, and the DCIS.com
in the 3D Matrigel culture was grown for an additional
10 days. The formation of spheroids was observed under
the fluorescence microscopy (Leica, Wetzlar, Germany).
RT-PCR and real-time RT-PCR
Total RNA was isolated using TRIzol reagent (Invitro-
gen, Carlsbad, CA) and was reverse-transcribed using
random hexamers and Superscript III reverse transcript-
ase. cDNAs were synthesized using M-MLV reverse
transcriptase (New England Biolabs, Ipswich, MA) and
specific primers. IL-6 and Interleukin 6 receptor (IL-6R)
mRNA expression levels were measured in single culture
and co-culture using the following primer sets (Add-
itional file 1: Table S1). Real-time RT-PCR reactions
were run on an ABI PRISM 7900 utilizing a SYBR Green
PCR master mix (Applied Biosystems, Foster City, CA).
Adipocyte-related genes such as peroxisome
proliferator-activated receptor-gamma (PPAR-γ) and
lipoprotein lipase (LPL) mRNA expression levels were
measured in single culture and co-culture using the spe-
cific primer sets (Additional file 1: Table S1). Results
were analyzed by the ΔCt method, which reflects the
threshold difference between a target gene and β-actin
in each sample.
Adipocyte differentiation and oil red O staining
Adipocyte differentiation was tested according to previously
published protocols [15]. hPreAd were cultured at a density
of 5000~ 6000 cells/cm2. After reaching confluence,
hPreAd was cultured in adipogenic medium containing
0.5 mM isobutyl-methylxanthine, 1 μM dexamethasone,
10 μM insulin, and 100 μM indomethacin for three days,
were maintained in medium with 10 μM insulin for 5 days
and were subjected to Oil Red O staining to detect
cytoplasmic triglycerides. Differentiated adipocytes were
rinsed twice with PBS and fixed in 10% formalin at room
temperature for 30 min. The working solution of Oil Red
O was prepared fresh before staining, and after the plate
completely dried, cells were stained for 30 min at room
temperature. Images of lipid droplets were acquired using a
microscope. For quantitative analysis of Oil Red O contents
levels, stained Oil Red O was eluted with isopropanol and
quantified by measuring the optical absorbance at 510 nm
with microplate reader (Bio-Rad, Hercules, CA).
Western blotting and immunofluorescence staining
Total cell lysates (50–100 μg) were separated by
SDS-PAGE and transferred onto a nitrocellulose
membrane. The membrane was incubated with specific
primary antibodies overnight at 4 °C, incubated with
horseradish peroxidase-conjugated secondary antibody,
and visualized with an ECL western blotting detection
reagents (Thermo Scientific, Rockford, IL). The
following primary antibodies were used in this study:
anti-phospho-mTOR, anti-mTOR, anti-phospho-AKT,
anti-AKT, anti-phospho-ERK1/2, anti-ERK1/2, anti-
phospho-STAT3 and anti-STAT3 antibodies (Cell
Signaling Technology, Danvers, MA); anti-phospho-FAK
antibody (Abcam, Cambridge, UK); anti-IL-6 and anti-
IL-6Rα antibodies (R&D Systems, Minneapolis, MN);
anti-FAK and anti-β-actin antibodies (Sigma, St. Louis,
MO). The relative intensity of the bands observed by
western blotting was analyzed using ImageJ software.
After 72 h single or co-culture in transwell chamber,
hPreAd was rinsed with ice-cold PBS and fixed with 4%
paraformaldehyde for 10 min at room temperature
followed by permeabilization with 0.1% sodium citrate plus
0.1% triton X-100. The cells were subjected to immuno-
fluorescence staining with anti-fibroblast-specific protein 1
(FSP1) (Millipore, Burlington, MA) and anti-α-smooth
muscle actin (α-SMC) (Abcam, Cambridge, UK) antibodies
for 2 h at room temperature. The cells were then washed
with cold PBS three times for 3 min each, and incubated
with Alexa 488-labeled secondary antibody at room
temperature for 1 h. Cell nuclei were stained with 4′,6-dia-
midine-2′-phenylindole dihydrochloride (DAPI) (Roche,
Berlin, Germany). The cells were examined by fluorescence
microscopy (Leica, Wetzlar, Germany).
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Measurement of secreted adipokines and cytokines
DCIS.com and hPreAd were cultured in transwell cham-
ber. After 48 h culture period, the conditioned media in
single or co-culture were collected, centrifuged between
5000 to 10,000 rpm for 10 min at 4 °C, filtered using
0.4 μm syringe filter, and stored at − 80 °C. The levels of
secreted adipokines and cytokines including adiponectin,
leptin, resistin, PAI-1, CCL2, CRP, TGF-β1, TGF-β2,
TGF-β3, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12(p70), IL-13,
GM-CGS, INF-γ, MMP-1, MMP-2, MMP-3, MMP-9,
MMP-12, and MMP-13 were quantified using the
Bio-Plex200 multiplex array system according to the
recommended protocol (Bio-Rad, Hercules, CA). All
samples and standardized solutions were analyzed in at
least three independent experiments.
Xenograft studies
All animal experiments were approved by the Seoul Na-
tional University Hospital Biomedical Research Institute
Animal Care and Use Committee (IACUC 13–
0350-C2A0(1)). A total of 16 female BALB/c nude mice
were used. Xenografts were established via the subcuta-
neous injection of 1 × 106 DCIS.com (n = 8) or a mixture
of 1 × 106 DCIS.com and 1 × 106 hPreAd cells (n = 8)
into the flank region of 5-week-old mice. Tumor-bearing
mice were randomly assigned to one of four groups:
DCIS.com (n = 4); DCIS.com+IL-6 NAb (n = 4); DCIS.-
com+hPreAd (n = 4); and DCIS.com+hPreAd+IL-6 NAb
(n = 4). At 7 and 12 day post-cancer cell injection, mice
were intravenously injected with IL-6 NAb (2 mg/kg).
Tumor volume was measured with digital calipers and
US imaging with a modified ellipsoidal formula for
volume (volume = 1/2(length×width2)) [16]. At 10 weeks
after the subcutaneous injection of DCIS.com, xenograft
tumors were removed.
Ultrasound (US) imaging analysis
US imaging of tumors was performed in B mode using a
preclinical Vevo2100 LAZR imaging system (Fujifilm
VisualSonics Inc., Toronto, Ontario, Canada) equipped
with a 40 MHz linear array transducer.
Histological analysis
The excised primary tumors were fixed with 4% buffered
formalin and embedded in paraffin blocks. Tissues were
sectioned into 4-μm thick sections. Paraffin sections were
deparaffinized in xylene and rehydrated in a series of
graded ethanol and water solutions. Hematoxylin and
eosin (H&E) staining was performed to evaluate the
change in cell and tissue structure. Histological images of
stained tissues were acquired by use of a microscope
equipped with a CCD camera (Leica, Wetzlar, Germany).
Statistical analysis
Statistical analysis was performed using Graph Pad
Prism software, and data were assessed by a two-tailed
Student’s t-test. The results were considered significant
when P < 0.05, and data are presented as the means ±
standard errors.
Results
Co-culture with DCIS.com inhibited adipogenic
differentiation of preadipocytes and induced the
expression fibroblast marker gene in preadipocytes
ER, PR and HER2 status in DCIS.com were determined
by real-time RT-PCR. DCIS.com belongs to the ER−/
PR−/HER2− and basal-like DCIS subtype as compared
with MCF-7 cells (ER+/PR+ subtype), SK-BR-3 cells
(HER2 subtype) and MDA-MB-231 cells (ER−/PR−/
HER2− subtype) (Additional file 1: Figure S1). To
investigate the effect of DCIS.com on the proliferation
and differentiation of hPreAd, indirect co-culture was
performed using transwell assays (Fig. 1a). A 72-h
co-culture of hPreAd with DCIS.com resulted in a sig-
nificant increase in hPreAd proliferation compared with
that of the single culture (1.58 ± 0.11 vs 1.0 ± 0.06, P =
0.001, Fig. 1b). After a 72-h co-culture of hPreAd with
DCIS.com in an in vitro transwell assay, we observed the
upregulated expression of two cancer-associated fibro-
blast markers, FSP1 and α-SMC, and a more elongated
cell shape, similar to fibroblast morphology (Fig. 1c).
The hPreAd exposed to DCIS.com-conditioned media
exhibited an upregulation in FSP1 and α-SMC expression
(Fig. 1d). During a 5-day co-culture, the differentiation abil-
ity of hPreAd into mature adipocytes was suppressed, and
there was a considerable decrease in the amount of lipid
droplets (0.56 ± 0.03 vs 1.0 ± 0.07, P < 0.0001, Fig. 1e). The
expression levels of adipocyte-related genes such as PPAR-γ
(1.00 ± 0.02 vs 0.21 ± 0.03, P < 0.0001) and LPL (1.00 ± 0.02
vs 0.19 ± 0.03, P < 0.0001) were also significantly decreased
in co-culture relative to single culture (Fig. 1f).
The proliferation, migration, and invasion of DCIS.com
were enhanced by co-culture with preadipocytes
To investigate the effect of hPreAd-secreted factors on
the proliferation, migration, and invasion of DCIS.com,
a transwell system was used. Proliferation of DCIS.com
was significantly increased in cells co-cultured with
hPreAd for 48 h (1.00 ± 0.04 vs 1.78 ± 0.16, P = 0.0007,
Fig. 2a). A significant increase in the migration of
DCIS.com co-cultured with hPreAd was observed com-
pared with that of the single culture (1.44 ± 0.14 vs 1.0
± 0.01, P = 0.009, Fig. 2b). A Matrigel-based cell inva-
sion assay revealed a similar stimulatory effect of
hPreAd on DCIS.com invasion (1.35 ± 0.11 vs 1.0 ±
0.03, P = 0.0126, Fig. 2c). The Matrigel invasion of
RFP-labeled DCIS.com into GFP-labeled hPreAd was
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reconstructed by 3D real-time confocal images. After
40 min, the invasion of DCIS.com was detected in
hPreAd embedded in Matrigel but not in Matrigel
without the presence of hPreAd (Fig. 2d). In evaluation
of the proliferation and migration of other breast
cancer cell lines (basal-like subtype, MDA-MB-231 and
HER2+/luminal-like subtype, SUM225) and normal
mammary epithelial cell (MCF10A) in co-culture with
hPreAd, an increase in proliferation and migration of
MDA-MB-231 cell increased but not SUM225 and
MCF10A cells (Additional file 1: Figure S2A and S2B).
In co-culture of the adipocyte differentiated from
hPreAd, the migration of DCIS.com and MDA-MB-231
cells was significantly increased, while the proliferation
of DCIS.com was suppressed (Additional file 1:
Figure S3A and S3B).
Fig. 1 Differentiation ability of human preadipocytes was suppressed by co-culture with DCIS.com, and human preadipocytes appear to revert to
a fibroblast phenotype. a Experimental scheme illustrating the transwell culture of DCIS.com (DCIS.com) and human preadipocytes (hPreAd). b
Proliferation analysis of hPreAd in single or co-culture was assessed by crystal violet assays of six independent experiments. c Analysis of
fibroblast-specific protein 1 (FSP1) and alpha-smooth muscle actin (α-SMC) expression in hPreAd in single or co-culture, as assessed by
immunostaining. Green: FSP1 or α-SMC-positive. Blue: nucleus. d Analysis of FSP1 and α-SMC expression in hPreAd treated with DCIS.com
conditioned medium (CM), as assessed by western blot. e Differentiation analysis of hPreAd in single or co-culture was assessed by Oil
Red O staining of six independent experiments. f Analysis of lipoprotein lipase (LPL) and peroxisome proliferator-activated receptor-gamma (PPAR-γ)
mRNA expression in hPreAd in single or co-culture, as assessed by RT-PCR and real-time RT-PCR of three independent experiments. All data are
presented as the means ± standard errors
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IL-6/IL-6R mediated cross-talk between DCIS.com and
preadipocytes is associated with the increased
proliferation and migration of DCIS.com
To identify the major factors secreted from hPreAd that
contribute to the proliferation migration, and invasion of
DCIS.com as shown in experimental scheme (Fig. 3a), we
analyzed the adipokines and cytokines in conditioned
media after 48 h of single or co-culture as indicated in
Table 1. Among the detected adipokines and cytokines,
the levels of adiponectin, MMP-9, and IL-2 secreted from
DCIS.com were higher than those of hPreAd, but the
levels of adipsin, PAI-1, CCL2, CRP, MMP-1, MMP-2,
MMP-3 and IL-6 secreted from hPreAd were higher than
those of DCIS.com. The other cytokines and adipokines
were either rarely detected or not detected. Intriguingly,
IL-6 expression levels (11,683 ± 678.3 pg/ml) were
approximately 2-fold higher in conditioned media from
co-culture than those from the hPreAd single culture
(6066 ± 138.7 pg/ml) (Fig. 3b, P = 0.0013). To further
investigate the change in IL-6 and IL-6 receptor mRNA
and protein expression levels in DCIS.com and hPreAd
after co-culture or treatment with conditioned media,
RT-PCR and western blotting were performed. IL-6
mRNA and protein expression levels were detected in
hPreAd, and IL-6R mRNA and protein expression levels
were detected in DCIS.com. A significant increase in the
mRNA and protein expression levels of IL-6 was observed
in hPreAd in co-culture and after treatment with condi-
tioned media compared to those in the single culture, and
the mRNA and protein expression levels of IL-6R were
not altered in DCIS.com in co-culture or after treatment
with conditioned media (Fig. 3c, d, and e).
Next, we investigated whether the IL-6-mediated
cross-talk between DCIS.com and hPreAd was involved in
breast cancer cell migration and proliferation. After IL-6
(50 ng/ml) was added to the culture medium of DCIS.com
alone for 48 h, DCIS.com proliferation (1.14 ± 0.01, P <
0.0001) and migration (1.33 ± 0.07, P = 0.002) were signifi-
cantly increased compared to those of the control cells
(Fig. 4a). The treatment with IL-6 (50 ng/ml) for 24 h–72 h
promoted migration of MCF10A but not SUM225 cells
(Additional file 1: Figure S4). After blocking IL-6 and IL-6R
with neutralizing antibodies in the single culture and
co-culture, the proliferation and migration of DCIS.com
Fig. 2 The proliferation, migration, and invasion abilities of DCIS.com were promoted by co-culture with human preadipocytes. Experimental scheme
illustrating the transwell culture of DCIS.com (DCIS.com) and human preadipocytes (hPreAd). a Proliferation analysis of DCIS.com in single
or co-culture, as assessed by crystal violet assay of six independent experiments. b Migration analysis of DCIS.com in single or co-culture,
as assessed by crystal violet assay of six independent experiments. c Invasion analysis of DCIS.com in single or co-culture, as assessed by
crystal violet assay of six independent experiments. d Fluorescence confocal images of DCIS.com migrating into hPreAd. All data are presented as the
means ± standard errors
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were evaluated using transwell assays. The treatment with
3 μg/ml IL-6NAb or IL-6RNAb in the single culture
resulted in a significant decrease of DCIS.com prolifera-
tion (0.92 ± 0.02, P = 0.03 and 0.92 ± 0.02, P = 0.03) but
not DCIS.com migration (Fig. 4b). DCIS.com proliferation
(1.75 ± 0.09, P < 0.0001) promoted by co-culture reverted
to a single culture state in the presence of 3 μg/ml IL-6
NAb or IL-6R NAb (1.21 ± 0.10, P = 0.0037 or 1.06 ± 0.07,
P = 0.0002), and migration (1.52 ± 0.04, P < 0.0001) en-
hanced by co-culture was also significantly decreased in
IL-6 NAb- or IL-6R NAb-treated DCIS.com (1.11 ± 0.02,
P < 0.0001 or 1.18 ± 0.09, P = 0.011) (Fig. 4c). The hPreAd
proliferation ability was significantly suppressed by IL-6
NAbs (0.66 ± 0.02, P < 0.0001) and IL-6R NAbs (0.59 ±
0.01, P < 0.0001) compared to that of the control cells (Fig.
4d). The effects of IL-6, IL-6 NAb or IL-6R NAb treat-
ment on spheroid colonies in a 3D Matrigel-based culture
system were evaluated. The spheroids were usually larger
in DCIS.com cultures treated with 50 ng/ml IL-6 or with
hPreAd conditioned media than in the untreated control,
but administration of 3 μg/ml IL-6 NAb or IL-6R NAb
caused the decrease in the spheroid diameter which had
been increased by hPreAd conditioned media (Fig. 4e).
We also investigated the phosphorylation of IL-6-trig-
gered signaling molecules in DCIS.com after the
administration of hPreAd conditioned media. The
phosphorylation levels of mTOR, FAK, AKT, and ERK1/
2 were increased in a time-dependent manner by the
administration of hPreAd conditioned media (Additional
file 1: Figure S5).
Fig. 3 IL-6 expression in human preadipocytes was increased by co-culture with human breast DCIS cells. a Experimental scheme illustrating the
transwell culture of DCIS.com (DCIS.com) and human preadipocytes (hPreAd). b Measurement of secreted IL-6 expression in single or co-culture,
as assessed by ELISA. Data are presented as the means ± standard errors of three independent experiments. c Analysis of IL-6 and IL-6 receptor
(IL-6R) mRNA expression levels in DCIS.com and hPreAd in single culture (S) or co-culture (C), as assessed by RT-PCR. d Analysis of IL-6 and IL-6R
protein expression levels in DCIS.com and hPreAd in single culture (S) or co-culture (C), as assessed by western blot. e Analysis of IL-6 and IL-6R
protein expression levels in DCIS.com and hPreAd treated with each conditioned medium (CM), as assessed by western blot
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Administration of IL-6 NAb suppressed tumor growth in a
mouse xenograft model
We finally explored the IL-6-mediated cross-talk be-
tween DCIS.com and hPreAd in a mouse xenograft
model. We observed the areas of carcinoma invading
into the adjacent adipose tissue in the xenograft tumors
obtained by co-injection of DCIS.com and preadipo-
cytes (Additional file 1: Figure S6A). Immunostaining
of IL-6 revealed that a significant staining for IL-6 was
found in fibroblast-like cells located at peritumoral area
not adipocytes (Additional file 1: Figure S6B). Fig. 5a
shows the schedule for evaluating the IL-6 NAb thera-
peutic effect in vivo. Using this regimen, two treat-
ments of IL-6 NAb (2 mg/kg) did not cause significant
changes in the body weights of mice compared with
those of untreated mice, suggesting the absence of
physical distress over the course of the experiment. To
investigate the in vivo therapeutic efficacy of IL-6 NAb
in tumors, we measured tumor volumes using US
imaging. Fig. 5b shows the US imaging of tumors in
each group at 10 weeks. As shown in Fig. 5c and d, the
tumor volumes were significantly increased in the mice
co-injected with DCIS.com and hPreAd (942.8 ±
163.0 mm3) relative to the mice injected with DCIS.-
com alone (527.1 ± 77.6 mm3, P = 0.0.027). The volume
of tumors treated with IL-6 NAb was decreased in the
mice co-injected with DCIS.com and hPreAd (207.8 ±
111.5 mm3, P = 0.012) or in the mice injected with
DCIS.com alone (338.1 ± 89.4, P = 0.154) relative to the
untreated mice. Progression of solid DCIS into
comedo-DCIS is initiated by naturally occurring apop-
tosis [15]. In H&E analysis of whole tumor tissue slides
a more invasive phenotype and large necrotic areas was
observed in hPreAd co-injected tumors relative to the
other tumors at 8–10 weeks post-injection, and the
treatment with IL-6 NAb inhibited tumor growth and
progression of DCIS.com in subcutaneous xenografts
(Fig. 5e), indicating that hPreAd promotes tumor
growth and progression of DCIS.com via IL-6-mediated
signaling.
Table 1 Cytokine and adipokine levels in conditioned medium of single or co-cultured human preadipocytes and MCF10DCIS.com cells
MCF10DCIS.com (pg/ml) Preadipocyte (pg/ml) Co-culture (pg/ml)
Adiponectin 116.5 ± 27.6 22.69 ± 13.6 74.2 ± 29.4
Leptin OOR< OOR< OOR<
Adipsin 2.2 ± 0.0 1236.0 ± 128.5 1129.0 ± 158.0
Resistin 44.6 ± 6.63 42.4 ± 4.9 43.8 ± 4.2
PAI-1 1069.0 ± 55.9 17,568.0 ± 1213.0 16,371.0 ± 1418.0
CCL2 1.3 ± 0.1 1825.0 ± 149.0 2160.0 ± 68.4
CRP 0.22 ± 0.0 2.53 ± 0.0 2.53 ± 0.0
TGF-β1 OOR< OOR< OOR<
TGF-β2 OOR< OOR< OOR<
TGF-β3 OOR< OOR< OOR<
IL-2 2.30 ± 0.3 OOR< OOR<
IL-4 0.26 ± 0.05 0.17 ± 0.0 0.17 ± 0.03
IL-5 0.26 ± 0.05 0.15 ± 0.02 0.17 ± 0.03
IL-6 20.8 ± 0.4 6066.0 ± 138.7 11,683.0 ± 678.3
IL-10 1.14 ± 0.06 0.77 ± 0.04 0.78 ± 0.04
IL-12(p70) 0.94 ± 0.03 0.81 ± 0.06 0.90 ± 0.03
IL-13 0.24 ± 0.06 0.24 ± 0.06 0.24 ± 0.0
GM-CSF 0.60 ± 0.27 OOR< OOR < −
INF-γ OOR< 0.91 ± 0.18 OOR<
TNF-α 1.93 ± 0.17 1.59 ± 0.13 1.82 ± 0.13
MMP-1 29.5 ± 1.6 908.6 ± 11.1 787.7 ± 18.9
MMP-2 360.0 ± 11.2 32,069.0 ± 6545 7284.0 ± 435.4
MMP-3 OOR< 665.8 ± 14.1 640.0 ± 32.5
MMP-9 775.7 ± 39.6 199.6 ± 3.6 192.3 ± 14.3
MMP-12 0.16 ± 0.16 OOR< OOR<
MMP-13 OOR< OOR< OOR<
OOR<, out of range below
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Fig. 4 Blocking IL-6 signaling with IL-6 neutralizing antibody or IL-6 receptor antibody abrogates the DCIS.com migration and proliferation enhanced
by co-culture with human preadipocytes. Experimental scheme illustrating the transwell culture and 3D culture of DCIS.com (DCIS.com) and human
preadipocytes (hPreAd). a Proliferation and migration analysis of DCIS.com treated with IL-6 (50 ng/ml), as assessed by MTT assay of six independent
experiments. b Proliferation and migration analysis of DCIS.com in the presence or absence of IL-6 neutralizing antibody (IL-6 NAb, 3 μg/ml) or IL-6
receptor antibody (IL-6Rα NAb, 3 μg/ml), as assessed by crystal violet assay of three independent experiments. c Proliferation and migration analysis
of DCIS.com in co-culture in the presence or absence of IL-6 neutralizing antibody (IL-6 NAb, 3 μg/ml) or IL-6 receptor antibody (IL-6Rα NAb, 3 μg/ml),
as assessed by crystal violet assay of six independent experiments. d Proliferation analysis of hPreAd in the presence or absence of
IL-6 neutralizing antibody (IL-6 NAb, 3 μg/ml) or IL-6 receptor antibody (IL-6Rα NAb, 3 μg/ml), as assessed by crystal violet assay of
six independent experiments. e Fluorescence microscopy images of DCIS.com spheroids in 3D Matrigel culture in the presence or absence of with
IL-6 (50 ng/ml), IL-6 NAb (3 μg/ml) or IL-6R NAb (3 μg/ml). All data are presented as the means ± standard errors
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Discussion
The importance of the tumor stromal cells surrounding
the DCIS in breast cancer progression has been recog-
nized. The role of fibroblast-like preadipocytes in breast
tumor progression at early stages is largely unknown.
Therefore, in this study, we explored the association of
preadipocytes with early stage breast tumor progression.
We demonstrated that IL-6 secreted from preadipocytes is
a crucial molecule in the cross-talk between preadipocytes
and DCIS cells in the early stage of breast cancer develop-
ment. In this study, we used DCIS.com cells, which are
derived from the non-cancerous breast epithelial cell line
MCF10A and compose the only human breast cancer cell
line that forms DCIS xenografts [16, 17], and preadipo-
cytes, which are isolated from human subcutaneous
adipose tissue. After co-culturing with preadipocytes,
DCIS.com proliferation and migration were significantly
promoted and the differentiation ability of preadipcytes
into mature adipocytes, as evidenced by the reduction in
lipid droplet formation and the expression of
adipocyte-related genes (PPAR-γ and LPL) was inhibited
by DCIS.com. IL-6 secretion was greatly increased by
co-culture with DCIS.com. Blocking the IL-6-mediated
cross-talk with neutralizing antibodies for IL-6 or IL-6R
inhibited the DCIS.com proliferation and migration that
was enhanced by co-culture with preadipocytes. In the
mouse xenograft model, tumor growth and the invasion
of primary tumor cells into stroma were promoted by
co-injection with preadipocytes. Blocking IL-6 signaling
by the intravenous injection of IL-6 neutralizing antibody
resulted in suppressed tumor growth compared with that
of the controls, which was monitored in vivo with US
imaging. Our study represents, to our knowledge, the first
trial to examine the impact of preadipocytes and IL-6 in
Fig. 5 Xenograft tumor volumes in mice were decreased by peritoneal injections of IL-6 neutralizing antibody. a In vivo experimental design and
treatment schedule with the IL-6 neutralizing antibody (IL-6 NAb, 2 mg/kg). b Ultrasound images of xenograft tumors from four mice in each
experimental group at 10 weeks post-injection and after two treatments of IL-6 NAb. Two orthogonal images in the X- and Y-axis were
obtained. c Gross images of the tumors removed from four mice in each group. Bar = 10 mm. d Tumor volumes (means ± standard errors)
measured from four mice in each group. e Representative H&E images of whole tumor tissue slides removed from mice in each group
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the use of DCIS cells as a breast cancer model of early
stage. We have demonstrated that the interaction between
human preadipocytes and breast DCIS cells significantly
changed the biological behavior of both preadipocytes and
breast carcinoma cells.
The role of the microenvironment in the regulation of
normal mammary gland function and the microenviron-
mental changes that occur in breast cancer have gained
attention [18]. The most abundant stromal component in
the breast is adipose tissue. In breast adipose tissue, prea-
dipocytes with a fibroblastic appearance become mature
adipocytes and maintain multipotency, readily differentiat-
ing into fibrogenic, osteogenic, and chondrogenic lineages
in vitro [19]. To date, very little is known regarding the
role of preadipocytes in mammary carcinogenesis. A
recent study found that preadipocyte-derived exosomes
enhance in vitro cell migration and the self-renewal of
DCIS cells and facilitated the xenograft tumor formation
of DCIS cells in vivo, suggesting that a number of
cytokines within preadipocyte-secreted exosomes might
contribute to DCIS tumor progression [14]. Likewise, we
found that co-culture with human preadipocytes or the
conditioned media of human preadipocytes promoted the
in vitro migration and proliferation of MCF10DCIS.com
(basal-like DCIS model) but not SUM225 (HER-2+/lu-
minal DCIS model). The studies by Dirat B et al. and
Manabe Y et al. [20, 21] showed the preadipocytes do not
enhance the migration, invasion or proliferation of ZR
75.1, MCF-7, and T47D (luminal-like subtype) in contrast
to SUM159PT (basal-like subtype). Their results are
similar to our data obtained from SUM225 (HER-2
+/luminal-like subtype) and DCIS.com and
MDA-MB-231 (basal-like subtype). Likewise, adipocytes
differentiated from preadipocytes remarkably enhanced
the migration of DCIS.com and MDA-231, but not
SUM225. Taken together, the impact of preadipocytes on
the proliferation and migration of breast tumor cells ap-
pears to the difference between basal-like and luminal-like
subtypes. Our results highlight that preadipocytes differ-
entially act on tumor cell proliferation and migration
depending on the intrinsic or molecular subtypes of breast
tumor cells and are able to more effectively stimulate the
proliferative and migratory capacities of basal-like breast
cancer cells. To evaluate this similarity and difference in
more detail, further studies regarding the production of
cytokines and adipokines in culture system are needed.
According to study reported by Bochet L et al. [22],
SUM159PT cells force mature adipocytes towards
fibroblast-like cells exhibiting elongated morphology and
expressing FSP1, but not α-SMA in adipose tissue, and
acquire more aggressive and invasive capability of tumor
cells. Similarly, our study demonstrated that DCIS.com
cells suppressed the differentiation of preadipocyte into
mature adipocyte, and made preadipocytes have more
elongated fibroblast morphology accompanying with the
upregulation of FSP1 and α-SMC, resulting in the acquisi-
tion of aggressive phenotype with a high proliferative and
migratory activity. These data, taken together, preadipo-
cytes and adipocyte-derived fibroblasts are morphologic-
ally and phenotypically similar to fibroblast-like cells and
have cooperative roles in promoting breast cancer pro-
gression. The further study to analyze gene expression
and signaling molecules in preadipocytes and
adipocyte-derived fibroblasts from co-culture with breast
cancer cells may provide large amounts of additional
information to define their similarities and differences of
biological functions. Taken together with such observa-
tions, we suggest that stromal cells including preadipo-
cytes and adipocyte-derived fibroblasts in the breast
tumor microenvironment represent attractive targets for
anti-cancer therapeutics.
Adipocytes are known to play a significant role in pro-
moting tumor progression by secreting cytokines includ-
ing IL-6, IL-1, IL-8, and TNF-α [20]. Adipose tissue is an
important source of circulating IL-6 [23]. IL-6 stimulates
lipolysis, and also inhibits adipose tissue lipoprotein lipase
activity in human adipose breast tissue [24]. IL-6 is
secreted by human adipose stromal cells which are
isolated from abdominal and breast adipose tissue and
also referred to as preadipocytes [7]. Expression of IL-6 is
greater in mouse preadipocytes (3 T3-L1 cell) than in
differentiated adipocytes, suggesting that preadipocytes
are the source of adipose tissue IL-6 [25]. Similarly, we
here found a significant staining for IL-6 in fibroblast-like
cells located at peritumoral area not adipocytes. Further-
more, tumor tissues co-injected with DCIS.com and
preadipocytes displayed stronger IL-6 staining than those
injected with DCIS.com alone. These results imply that
IL-6 positive fibroblast-like cells which can be derived
from preadipocytes and adipocytes may play an important
role in DCIS tumor growth and invasive progression.
IL-6 is an autocrine and paracrine regulator in cell pro-
liferation, survival, and metabolism, but has lesser actions
on adipose tissue [23]. IL-6/IL-6 receptor mediated signal-
ing leads to activation of the JAK family of tyrosine
kinases, which then stimulate multiple pathways involving
MAPKs, PI3Ks, STATs, and other signaling proteins [26].
IL-6-mediated signaling modulates cell migration and the
epithelial to mesenchymal transition of ER-positive breast
DCIS cells ZR-75-1 via the down-regulation of E-cadherin
[27]. A recent study showed that the IL-6 signaling be-
tween human breast DCIS cells (DCIS.com and SUM102)
and stromal fibroblasts represents an important factor in
the initiation of DCIS cell progression to invasive breast
carcinoma [28]. In the present study, we observed high
IL-6 expression in human preadipocytes co-cultured with
DCIS.com as well as increased phosphorylation of mTOR,
AKT, ERK and STAT3 in DCIS.com treated with
Kim et al. Journal of Experimental & Clinical Cancer Research  (2018) 37:200 Page 11 of 13
conditioned media of human preadipocytes. Moreover,
IL-6 treatment caused a significant increase in DCIS.com
cell proliferation and migration, but no additional migra-
tion effect of IL-6 on SUM225 was observed, indicating
that the sensitivity to IL-6 is absent in SUM225 or the dif-
ferent factors involved in the reciprocal cross talk between
preadipocytes and SUM225 may not exert significant
effects on migration of SUM225 cells. Our data, together
with our findings that implicate IL-6 secreted by preadipo-
cytes in breast cancer progression from basal-like DCIS,
strongly support a working hypothesis that resident
preadipocytes in local adipose stromal tissues and their
secretory factor IL-6 play a key role in mediating the
progression of early stage breast cancer.
We aimed to identify the most important soluble
factor secreted from human preadipocytes that promotes
the invasion ability of DCIS.com and tumor growth in
the reciprocal communication between the preadipo-
cytes and DCIS.com. After extensively examining the
changes in cytokines and adipokines in co-culture
medium, we found a significant upregulation in IL-6
expression. Co-culture with hPreAd and treatment with
IL-6 promoted the migration and proliferation ability of
DCIS.com, whereas treatment with IL-6 NAb or IL-6R
NAb abrogated the DCIS.com migration and prolifera-
tion enhanced by co-culture with hPreAd. Our current
results are in accordance with previously published
studies [14, 27] and indicate that IL-6/IL-6R mediated
signaling is a critical therapeutic target for inhibiting
early stage breast tumor progression.
Clinical studies have revealed that a high serum expres-
sion level of IL-6 in patients is associated with advanced
tumor stages in various cancers (multiple myeloma,
non-small cell lung carcinoma, colorectal cancer, renal cell
carcinoma, prostate cancer, breast cancer and ovarian can-
cer) [29–32]. Moreover, IL-6 is associated with a poor
prognosis in breast cancer patients [33]. Therefore, block-
ing IL-6 signaling is a potential therapeutic strategy for
cancer patients. The IL-6 antibody (siltuximab, CNTO
328) and IL-6 receptor antibody (tocilizumab) belong to a
class of therapeutics clinically approved for patients with
malignant cancers, including prostate, ovarian, and lung
cancers [29–32]. In our study, notably, blocking IL-6 sig-
naling with intravenous injections of IL-6 neutralizing
antibodies suppressed xenograft tumor growth, suggesting
that IL-6 signaling would be therapeutic target for inhibit-
ing early stage breast tumor progression.
Conclusions
In summary, we propose that IL-6 is an important mediator
involved in the cross-talk between preadipocytes and breast
DCIS cells, which is associated with early stage breast
cancer progression. Therefore, blocking IL-6 signaling
might be a potential therapeutic strategy for breast DCIS
characterized by pathological IL-6 overproduction. Deci-
phering the critical factor behind preadipocyte-breast DCIS
cell cross-talk might provide new targets for improving
breast cancer diagnosis and for the design of innovative
therapeutic strategies.
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